ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.557,27
-0,48%
S&P 500
5.346,99
-0,11%
Dow Jones
38.798,99
-0,22%
Euro vs US Dollar
1,08165
0,00%
Bitcoin
69.394,88
0,09%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Apellis Pharmaceuticals Inc (APLS)

  7. Apellis Pharmaceuticals Inc (APLS) News

APLS

Apellis Pharmaceuticals (APLS)

Apellis Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:APLS
DatumZeitQuelleÜberschriftSymbolFirma
05/06/202422h50Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APLSApellis Pharmaceuticals Inc
05/06/202413h00GlobeNewswire Inc.Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:APLSApellis Pharmaceuticals Inc
24/05/202416h00GlobeNewswire Inc.Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA CongressNASDAQ:APLSApellis Pharmaceuticals Inc
21/05/202422h03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:APLSApellis Pharmaceuticals Inc
14/05/202414h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APLSApellis Pharmaceuticals Inc
14/05/202414h00GlobeNewswire Inc.Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth StreetNASDAQ:APLSApellis Pharmaceuticals Inc
09/05/202423h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:APLSApellis Pharmaceuticals Inc
08/05/202423h13Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:APLSApellis Pharmaceuticals Inc
07/05/202413h05GlobeNewswire Inc.Apellis Pharmaceuticals Reports First Quarter 2024 Financial ResultsNASDAQ:APLSApellis Pharmaceuticals Inc
07/05/202413h02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:APLSApellis Pharmaceuticals Inc
06/05/202413h00GlobeNewswire Inc.Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare ConferenceNASDAQ:APLSApellis Pharmaceuticals Inc
01/05/202413h00GlobeNewswire Inc.Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual MeetingNASDAQ:APLSApellis Pharmaceuticals Inc
26/04/202413h15GlobeNewswire Inc.Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)NASDAQ:APLSApellis Pharmaceuticals Inc
23/04/202413h00GlobeNewswire Inc.Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial ResultsNASDAQ:APLSApellis Pharmaceuticals Inc
04/04/202422h05GlobeNewswire Inc.Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:APLSApellis Pharmaceuticals Inc
01/04/202413h00GlobeNewswire Inc.Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:APLSApellis Pharmaceuticals Inc
11/03/202421h08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:APLSApellis Pharmaceuticals Inc
11/03/202412h00GlobeNewswire Inc.Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina AdvisorNASDAQ:APLSApellis Pharmaceuticals Inc
08/03/202422h10Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:APLSApellis Pharmaceuticals Inc
08/03/202413h45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:APLSApellis Pharmaceuticals Inc
06/03/202422h05GlobeNewswire Inc.Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:APLSApellis Pharmaceuticals Inc
05/03/202422h07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:APLSApellis Pharmaceuticals Inc
05/03/202422h04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:APLSApellis Pharmaceuticals Inc
01/03/202422h25Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:APLSApellis Pharmaceuticals Inc
01/03/202419h37Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:APLSApellis Pharmaceuticals Inc
29/02/202423h10Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:APLSApellis Pharmaceuticals Inc
27/02/202413h35Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:APLSApellis Pharmaceuticals Inc
27/02/202413h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APLSApellis Pharmaceuticals Inc
27/02/202413h05GlobeNewswire Inc.Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:APLSApellis Pharmaceuticals Inc
27/02/202413h01Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:APLSApellis Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:APLS

Kürzlich von Ihnen besucht

EU
SPLR
Leverage Shares 1x Short...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten